EryDel is a multi-asset, clinical stage biopharmaceutical company headquartered in Bresso (Milan), Italy dedicated to developing and commercializing novel treatments for rare diseases with high unmet need. In 2018 EryDel received the “Most Innovative StartUp Italia Award” chosen from startups across all industries. EryDel specializes in the delivery of drugs using the patient’s own red blood cells. The lead product candidate, EryDex, is currently in Phase III development for the treatment of Ataxia Telangiectasia (AT), a rare neurological disorder for which no established therapy is currently available. EryDex received Orphan Drug designation for the treatment of AT both from FDA and EMA
Location: Italy, Lombardy, Bresso
Employees: 11-50
Total raised: $32.43M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.04.2018 | - | $32.43M | - |
Mentions in press and media 3
| Date | Title | Description |
| 05.04.2022 | EryDel to Present its Phase 3 Study Results for Ataxia Telangiectasia at the American Academy of Neurology 2022 Annual Meeting | BRESSO (MILANO), ITALY / ACCESSWIRE / April 5, 2022 / EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technolog... |
| 24.04.2018 | EryDel Raises €26.5M in Financing | EryDel, a Milan, Italy-based biotech company, raised €26.5M in financing. The round was led by Sofinnova Partners with participation from existing shareholder Genextra SpA and Innogest SGR. The company intends to use the funds to boost its ... |
| 24.04.2018 | Sofinnova leads $32.4 million round for Italy's EryDel; Celgene expands collaboration with Zymeworks | → Having followed Milan-based EryDel and its CEO for years, Sofinnova Partners is jumping in for the ride, leading its latest €26.5 million ($32.4 million) round. The funds will cover the registrational Phase III clinical t... |